Analytical Data
-
Gene name
JAK2
- Application
-
Alternative Names
JTK10; Tyrosine-protein kinase JAK2
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O60674
-
Expression Region
Asn508~Ala800
-
Molecular Weight
35kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
JAK2 (Janus kinase 2) is a crucial intracellular enzyme that plays a significant role in the signaling pathways of hematopoietic and immune cells, particularly in response to various cytokines and growth factors. Research on JAK2 has gained momentum due to its association with several hematological malignancies, most notably polycythemia vera, essential thrombocythemia, and myelofibrosis, which are characterized by mutations in the JAK2 gene. The most common mutation, JAK2 V617F, leads to constitutive activation of the kinase, resulting in uncontrolled cell proliferation and survival. This aberrant signaling pathway has made JAK2 an attractive target for therapeutic intervention, and several JAK2 inhibitors are currently in clinical use or trial phases. Furthermore, the study of JAK2 recombinant proteins is essential for understanding its structural and functional properties, elucidating the mechanisms of signaling, and developing novel therapeutics. By producing and characterizing recombinant JAK2, researchers can explore protein interactions, validate mutation effects, and assess drug efficacy, ultimately contributing to better management strategies for JAK2-related disorders. The ongoing research in this domain not only improves our understanding of JAK2 biology but also holds promise for innovative treatments targeting the JAK2 pathway in various diseases.
